Šmíd

Palisade Promotes Dawn R. Brock and Garo Norian to Associate Portfolio Manager Roles; Retains Search Firm

Retrieved on: 
Tuesday, January 9, 2024
Stanford University, Public utility, Columbia Business School, Health care, LP, Lord Abbett, Fordham University, Associate, Research, Partner, Journalism, CFA, BlackRock, Growth, Šmíd, Investment management, J. P. Morgan, Management, Analyst, Global Industry Classification Standard

Dawn Brock joined Palisade in 2013 as a Senior Research Analyst with a focus on the Health Care sector, and she was named a Partner in the firm in 2023.

Key Points: 
  • Dawn Brock joined Palisade in 2013 as a Senior Research Analyst with a focus on the Health Care sector, and she was named a Partner in the firm in 2023.
  • Prior to joining Palisade, Ms. Brock was at Lord Abbett & Co., LLC where she was an Investment Analyst covering Health Care.
  • Dan Veru, Palisade Senior Partner and Chief Investment Officer commented, "These well-earned promotions are a natural progression for both Dawn and Garo.
  • These promotions signify our confidence in both Dawn and Garo and our commitment to the continued growth of our firm."

Actinium Pharmaceuticals, Inc. to Present at the 3rd Annual B. Riley Securities Oncology Conference

Retrieved on: 
Tuesday, January 17, 2023
Immunotherapy, Conference, Šmíd, Patient, KOL, NYSE, Cancer, Online shopping, Medical imaging, Pharmaceutical industry, Actinium

NEW YORK, Jan. 17, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company's management team will participate in a fireside chat on Thursday, January 19, 2023 at 10:30 AM EST at the 3rd Annual B. Riley Securities Oncology Conference.

Key Points: 
  • NEW YORK, Jan. 17, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company's management team will participate in a fireside chat on Thursday, January 19, 2023 at 10:30 AM EST at the 3rd Annual B. Riley Securities Oncology Conference.
  • The webcast of the presentation will be accessible on the event's website at https://brileyoncology22.sequireevents.com/ and on the investor relations page of Actinium's website https://ir.actiniumpharma.com/ .
  • A replay of the presentation will be available on the day of the fireside chat through the same links.
  • B. Riley Securities 3rd Annual Oncology Conference, January 18-19, will feature over 30 SMiD cap healthcare companies focused on the development and commercialization of new medicines and key enabling technologies, cutting across multiple next-generation therapeutic modalities.

Pyramid Biosciences to Present at the B. Riley Securities Third Annual Oncology Conference

Retrieved on: 
Wednesday, January 18, 2023
Biotechnology, Health, Science, Research, Oncology, Immunotherapy, Conference, Šmíd, Patient, Radiation, Cancer, Pharmaceutical industry

Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, has announced its participation this week in the B. Riley Securities 3rd Annual Oncology Conference.

Key Points: 
  • Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, has announced its participation this week in the B. Riley Securities 3rd Annual Oncology Conference.
  • Its Chief Executive Officer, Dr. Brian Lestini, will present on Thursday, January 19, 2023, at 2 PM ET.
  • Highlights include panel discussions with academic and industry key opinion leaders at the forefront of translational and clinical research.
  • Topics span novel immunotherapy, cell therapy, and targeted oncology approaches, as well as imaging and radiation oncology initiatives aimed at driving meaningful improvements to current standard of care for cancer patients.

Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference

Retrieved on: 
Tuesday, January 17, 2023
Immunotherapy, Hematological Cancer Research Investment and Education Act, Conference, Šmíd, EST, Patient, Translation, KOL, Cancer, Medical imaging

B. Riley Securities’ 3rd Annual Oncology Conference, January 18-19, 2023, will feature over 30 SMiD cap healthcare companies focused on the development and commercialization of new medicines and key enabling technologies, cutting across multiple next-generation therapeutic modalities.

Key Points: 
  • B. Riley Securities’ 3rd Annual Oncology Conference, January 18-19, 2023, will feature over 30 SMiD cap healthcare companies focused on the development and commercialization of new medicines and key enabling technologies, cutting across multiple next-generation therapeutic modalities.
  • The conference will feature KOL panel discussions with academic and industry leaders at the forefront of translational and clinical research underway with novel immunotherapy, cell therapy, and targeted oncology approaches, as well as imaging and radiation oncology initiatives, aimed at driving meaningful improvements to current standard of care for cancer patients.
  • For more information and to register for the conference, please click here .
  • A replay of the fireside chat will also be available on the registration link after the meeting.

MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference

Retrieved on: 
Wednesday, January 11, 2023
Immunotherapy, Conference, Šmíd, Mink, Patient, KOL, Therapy, Cancer, Pharmaceutical industry

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET.

Key Points: 
  • NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET.
  • Access to the live fireside chat is available at https://brileyoncology22.sequireevents.com/ .
  • Following the fireside chat, a replay will be available on the Events and Presentations page of the MiNK website at https://investor.minktherapeutics.com/events-and-presentations .
  • B. Riley Securities 3rd Annual Oncology Conference, January 18-19, will feature over 30 SMiD cap healthcare companies focused on the development and commercialization of new medicines and key enabling technologies, cutting across multiple next-generation therapeutic modalities.

Accuray to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Retrieved on: 
Tuesday, January 10, 2023
Šmíd, Cancer, Patient, Conference, Immunotherapy, KOL, Fireside chats, Fireside

SUNNYVALE, Calif., Jan. 10, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the B. Riley Securities' 3rd Annual Oncology Conference taking place January 18-19, 2023. The management team is scheduled to participate in a virtual Fireside Chat on Wednesday, January 18, 2023 at 7:00am PST/10:00am EST.

Key Points: 
  • Company to Take Part in Fireside Chat Wednesday, January 18, 2023 at 7:00am PST/10:00am EST
    SUNNYVALE, Calif., Jan. 10, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the B. Riley Securities' 3rd Annual Oncology Conference taking place January 18-19, 2023.
  • The management team is scheduled to participate in a virtual Fireside Chat on Wednesday, January 18, 2023 at 7:00am PST/10:00am EST.
  • A live webcast of the Fireside Chat can be accessed on the Accuray website at investors.accuray.com .
  • B. Riley Securities 3rd Annual Oncology Conference, January 18-19, will feature over 30 SMiD cap healthcare companies focused on the development and commercialization of new medicines and key enabling technologies, cutting across multiple next-generation therapeutic modalities.

Rockefeller Asset Management Expands Team to Scale Existing Capabilities and Position Growth Centered on Strategic Partnerships

Retrieved on: 
Thursday, October 20, 2022
Banking, Asset Management, Professional Services, Finance, FSA, PIMCO, Growth, UCITS, ESG, RAM, Engagement, Research, Credit Suisse, Company, Johns Hopkins University, University, Goldman Sachs, Columbia University, Šmíd, First Eagle Investment Management, Kotík, Harvard University, Morgan Stanley, Rockefeller, High-net-worth individual, Bloomberg, Retirement, Russell Investments, Leadership, Financial services, Security (finance), Management, Economics, Boston College

Rockefeller Asset Management (RAM), the asset management division of Rockefeller Capital Management, today announced three appointments aimed at maximizing investment performance for clients and the role of strategic partnerships in the growth of the divisions business.

Key Points: 
  • Rockefeller Asset Management (RAM), the asset management division of Rockefeller Capital Management, today announced three appointments aimed at maximizing investment performance for clients and the role of strategic partnerships in the growth of the divisions business.
  • He holds a bachelors degree in Business from the University of Delaware and a masters in Business from Johns Hopkins University.
  • As of September 30, 2022, the Firm was responsible for approximately $90 billion in client assets across its three business segments, the Rockefeller Global Family Office, Rockefeller Asset Management and Rockefeller Strategic Advisory.
  • As of September 30, 2022, Rockefeller Asset Management had $9.5 billion in assets under management.

First Eagle Investments Launches US Smid Cap Opportunity Fund

Retrieved on: 
Wednesday, August 17, 2022
Finance, Consulting, Banking, Professional Services, Other Professional Services, First Eagle Investment Management, Salamone, Exercise, Risk, Fund, Growth, Investment, Prospectus, Royce Investment Partners, LLC, AUM, Government, SIPC, First, Acquisition, Judgement, Šmíd, FDIC, Head, Eagle, Security (finance), Financial adviser, Financial services, Cryptocurrency, Bank, Sheehy

First Eagle Investments (First Eagle) today announced the launch of the First Eagle US Smid Cap Opportunity Fund (A-Share Class: FEMAX; I-Share Class: FESMX; R6-Share Class: FEXRX).

Key Points: 
  • First Eagle Investments (First Eagle) today announced the launch of the First Eagle US Smid Cap Opportunity Fund (A-Share Class: FEMAX; I-Share Class: FESMX; R6-Share Class: FEXRX).
  • Were excited to leverage our Small Cap teams time-tested approach to value-oriented investment across a broader opportunity set for investors in pursuit of small and midcap equity exposure through our new US Smid Cap Opportunity Fund.
  • Given the enhanced liquidity of the smid cap space, the US Smid Cap Opportunity Fund typically will hold approximately 70100 stocks.
  • The First Eagle U.S. Smid Cap Opportunity Fund is new and may not be successful under all future market conditions.